Aim: To evaluate the lipid-lowering efficacy and safety of evolocumab combined with background atorvastatin in patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia.
Elevated low-density lipoprotein cholesterol (LDL-C) has been associated with cardiovascular events in patients with type 2 diabetes mellitus (T2DM). 4, 5 Statins are the first-line therapy for LDL-C reduction and primary and secondary prevention of atherosclerotic CVD (ASCVD) events in patients with and without T2DM. [6] [7] [8] [9] [10] [11] [12] The Cholesterol Treatment Trialists' Collaborators meta-analysis showed that every mmol/L reduction in LDL-C is associated with a 21% reduction in the incidence of any major vascular event, and the effect is similar in patients with or without diabetes. 13 However, an unmet medical need remains for patients who are unable to reach recommended LDL-C levels with a statin alone, who are unable to take an effective dose, or who are statin intolerant. 12, [14] [15] [16] [17] Thus, additional lipidlowering therapies for achieving recommended LDL-C levels and reducing cardiovascular risk are needed for this high-CVD risk patient population.
In phase 2 and 3 clinical studies, evolocumab, a human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), consistently reduced LDL-C levels in patients on background statin alone or in combination with lipid-lowering therapy. [18] [19] [20] [21] [22] [23] In the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial (NCT01764633), evolocumab reduced the risk of major cardiovascular events (myocardial infarction, stroke, and coronary revascularization) in patients with or without diabetes. 24 In the evolocumaB Efficacy for LDL-C Reduction in subjectS with T2DM On background statiN (BERSON) study,
we assessed the efficacy and safety of evolocumab combined with background atorvastatin in reducing LDL-C and improving other lipid levels in a global population of patients with T2DM and hyperlipidaemia or mixed dyslipidaemia. Of note, unlike post hoc and pooled analyses of evolocumab in patients with T2DM, this study included patients with worse diabetes control at baseline (e.g. elevated HbA1c). Approximately 50% of the patients in BERSON were enrolled at centres in China; a prespecified analysis of the efficacy and safety of evolocumab in the China population is reported by Chen at al. 25 2 | METHODS
| Study design and participants
BERSON (ClinicalTrials.gov, NCT02662569) was a 12-week, randomised, double-blind, placebo-controlled, phase 3 study conducted at 98 centres in 10 countries (Argentina, Brazil, Canada, China, Colombia, France, Republic of Korea, Russian Federation, Turkey, and the United States). This global study was designed to recruit one half of its patients from China. The design and rationale of the study have been described in detail previously. 26 The primary objective of the study was to evaluate the efficacy versus placebo of 12 weeks of subcutaneous evolocumab administered every 2 weeks (Q2W) or monthly (QM) combined with oral atorvastatin 20 mg once daily (QD) on the percentage change from baseline in LDL-C level.
Eligible patients were ≥18 to ≤80 years of age with T2DM, were receiving stable pharmacological therapy for diabetes for ≥6 months, and had HbA1c ≤10% and fasting triglycerides ≤4.5 mmol/L (≤400 mg/dL). Patients on statin therapy at screening were required to have an LDL-C of ≥2.6 mmol/L (≥100 mg/dL); those not on statin therapy at screening were required to have an LDL-C of ≥3.4 mmol/L (≥130 mg/dL). Lipid-lowering therapy status had to be unchanged for ≥4 weeks before LDL-C screening. Key exclusion criteria were medical contraindications to receiving 20 mg atorvastatin; New York Heart Association (NYHA) III or IV heart failure; myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 6 months before randomization; eGFR <30 mL/min/1.73m 2 at screening. Full exclusion criteria are provided in Supporting Information Table S1 .
| Ethics
This study was conducted in accordance with the guidelines on good clinical practice and with ethical standards for human experimentation established by the Declaration of Helsinki. An independent review board or independent ethics committee at each study site reviewed the study and approved the protocol and the subsequent amendments to the study protocol. An external, independent data monitoring committee (DMC) periodically reviewed study data, and analyses for the DMC were provided by an independent biostatistical group. All patients provided written, informed consent before participation. 27, 28 Given that approximately half of the patients were recruited at centres in China, atorvastatin 20 mg QD was selected for the study based on Chinese dyslipidaemia guidelines and the anticipated LDL-C response in Chinese patients. 29, 30 Justification for the study length was described previously. 26 The last dose of evolocumab or placebo was administered at week 8 for QM patients and week 10 for Q2W patients. The final study visit was at week 12 for QM patients and by telephone follow-up at week 14 for Q2W patients.
| Randomization and study procedures
Randomization was based on a computer-generated randomization sequence with an interactive voice response system and was stratified by entry statin therapy (no statin use vs. non-intensive statin use) and the study centre's geographic region. Treatment assignment was blinded to the sponsor study team, investigators, site staff, and patients throughout the study. family-wise error rate at 0.05. 33 Baseline covariates included stratification factors, age, sex, race, baseline LDL-C, family history of premature coronary heart disease, baseline PCSK9, body mass index, hypertension, current smoker, ≥2 baseline CHD risk factors, and triglycerides. The co-secondary endpoint of LDL-C target achievement was assessed using the Cochran-Mantel-Haenszel test adjusted by the stratification factors. Safety assessments were summarized descriptively.
| Study assessments
3 | RESULTS
| Patients
The Demographics and baseline clinical characteristics were generally balanced between the evolocumab and placebo groups (Table 1) .
Most patients (57.3%) were female, and the mean age was 61.3 years.
As anticipated, approximately half (49.9%) of patients were Asian, with 45.9% of patients enrolled at centres in China. Baseline lipid variables were generally consistent between treatment groups ( Table 1 ).
The mean (SD) serum concentration of LDL-C at baseline was 2.4 
| Efficacy
Compared with placebo, evolocumab treatment reduced LDL-C by a least-squares mean of 71.8% (95% CI, −77.6 to −65.9; P < 0.0001) with Q2W dosing and 64.9% (−70.0 to 59.9; adjusted P < 0.0001)
with QM dosing at week 12, and by 70.3% (−75.4 to −65.2; adjusted P < 0.0001) with Q2W dosing and 70.0% (−74.7 to −63.4; adjusted P < 0.0001) with QM dosing at the mean of weeks 10 and 12 ( Table 2 ).
The treatment effect in LDL-C by scheduled visits and treatment groups for Q2W and QM regimens is shown in Figure 2 . LDL-C concentrations were reduced to below 70 mg/dL (1.8 mmol/L) in 88%
and 90% of patients in the evolocumab Q2W and QM groups, respectively, at week 12, and in 90% and 91% of patients in the evolocumab Q2W and QM groups, respectively, at the mean of weeks 10 and 12 ( Table 2 ). Subgroup analyses of the co-primary endpoints showed treatment effects that were consistent with those observed in the global study population.
Changes from baseline in secondary lipid variables are summarized in Table 2 . Treatment with evolocumab, compared with placebo, similarly resulted in statistically significant improvements in non-HDL-C from baseline to week 12 (Q2W, −61.6%, adjusted P < 0.0001; QM, −54.2%, adjusted P < 0.0001) and to the mean of weeks 10 and 12 (Q2W, −60.9%, adjusted P < 0.0001; QM, −59.4%, adjusted P < 0.0001; Figure 3 ). Treatment with evolocumab also resulted in significant improvements in ApoB100, triglycerides, Lp(a), and HDL-C.
| Safety and immunogenicity
The overall incidence of AEs was similar between patients who received evolocumab and placebo, with 288 (43.8%) and 138 (42.6%) patients, respectively, having an AE (Table 3 ). Most were grade 1 (placebo, 13.6%; evolocumab, 14.0%) or 2 (placebo, 23.5%; evolocumab, (Table 3) .
Serious AEs (SAEs) occurred in 32 (4.9%) patients in the evolocumab group and 11 (3.4%) patients in the placebo group. There were no single SAEs reported in ≥1% of patients in either the evolocumab or placebo groups. SAEs were considered not related to study drug by the investigators, except for gastric ulcer (one patient, evolocumab) and lacunar stroke (one patient, evolocumab). No deaths occurred during the study.
One patient in the evolocumab QM group tested positive for antievolocumab binding antibodies at baseline; no patients tested positive for binding or neutralizing antibodies during the study.
| DISCUSSION
BERSON is the largest (n = 986) dedicated T2DM study with a PCSK9
inhibitor to date. Treatment with evolocumab 140 mg Q2W and 420 mg QM, compared with placebo, with moderate intensity Treatment difference is from the repeated measures linear effects model, which included treatment group, stratification factors, scheduled visit, and the interaction of treatment with scheduled visit as covariates for all endpoints except LDL-C achievement. b Adjusted P value is based on a combination of sequential testing, the Hochberg procedure, which is a fallback procedure to control the overall significance level for all primary and secondary endpoints. Each individual adjusted P value is compared with 0.05 to determine statistical significance.
background atorvastatin, led to significant reductions in LDL-C concentrations over 12 weeks. For diabetic patients with ASCVD or without ASCVD and at least one additional risk factor, The American
Association of Clinical Endocrinologists/American College of Endocrinology and American Diabetes Association guidelines recommend the addition of ezetimibe or a PSCK9 inhibitor when recommended LDL-C levels (<1.8 mmol/L) are not achieved with maximally tolerated statin therapy. 11 In BERSON, evolocumab treatment allowed the vast majority of patients to achieve LDL-C levels <1.8 mmol/L (Q2W, 88%-90%;
QM, 90%-91%). A mean absolute reduction in LDL-C of 1.62 and 1.64 mmol/L, Q2W and QM, respectively, was observed in the evolocumab group versus the placebo group. In FOURIER, a mean absolute reduction of 1.45 mmol/L at 48 weeks was associated with a 16% (95% CI, 4 to 26) risk reduction in the composite of cardiovascular death, myocardial infarction, or stroke, and the magnitude of the risk reduction increased beyond the first year. 34 Furthermore, robust improvements in non-HDL-C and ApoB100 were observed with evolocumab compared with placebo on background atorvastatin, both targets for therapy in patients with T2DM and in whom the addition of a non-statin therapy is recommended when desired levels are not achieved with maximally tolerated statin therapy.
11
The reductions in LDL-C and non-HDL-C observed in BERSON are consistent with the results of the BANTING study (also a dedicated type 2 diabetes trial), as well as previous prespecified and post hoc (DESCARTES) analyses of other phase 3 evolocumab studies. In the 12-week, randomised, double-blind phase 3 BANTING study, treatment with evolocumab decreased LDL-C by 65% and non-HDL-C by 56%
versus placebo in patients with T2DM and hypercholesterolaemia or mixed dyslipidaemia on background statin therapy. 35 In a meta-analysis of three 12-week phase 3 studies of patients with hypercholesteraemia and T2DM, evolocumab reduced LDL-C by 60% and non-HDL-C by 55% compared with placebo. 36 Similar results were observed in a post hoc analysis by baseline glycaemic status from the 52-week DES-CARTES study in patients with hypercholesterolemia. 18 In the prespecified analysis of patients with (n = 11 031) and without EvoMab 140 mg Q2W (n = 325) PBO Q2W (n = 164) EvoMab 420 mg QM (n = 332) PBO QM (n = 160) FIGURE 2 Mean percentage change in LDL-C from baseline to scheduled visits in LDL-C for (A) Q2W dosing and (B) QM dosing. Vertical lines represent the standard error around the mean. No imputation was used for missing values. When the calculated LDL-C was <1.0 mmol/L or triglycerides were >4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation LDL-C from the same blood sample, if available therapy (almost 70% on high-intensity and 30% on moderate intensity). 24 Of note, the LDL-C lowering effect significantly reduced cardiovascular risk with similar efficacy in patients with and without diabetes;
however, because of the higher baseline risk, the absolute risk reduction was greater in patients with diabetes. 24 Likewise, significant LDL-C and non-HDL-C reductions were seen after 24 weeks of treatment with the PCSK9 inhibitor alirocumab in patients with T2DM. 37, 38 In this study, evolocumab combined with moderate intensity atorvastatin was well tolerated and the overall incidence of AEs was consistent with previous reports. 35, 36 The imbalance in AEs of diabetes in the evolocumab group was not surprising given that, at baseline, insulin use was higher and glycaemic control was worse in the evolocumab group than in the placebo group, as evidenced by the greater baseline median HbA1c and FPG levels. In the BANTING study, where FSG, HbA1c, and insulin use were balanced between groups, no difference in diabetes AEs was observed (placebo, 3.5%; evolocumab, 2.9%). Occurring in at least 1% of patients in evolocumab treatment group. b Includes preferred terms of diabetes mellitus (placebo, 1.9%; evolocumab, 4.6%) and type 2 diabetes mellitus (placebo, 0.6%; evolocumab, 1.2%).
c Patient was assigned to QM dosing, reported at week 8 visit, remained asymptomatic, and returned to baseline at week 12. d Patient was assigned to QM dosing, reported at week 8 and 12 visits, remained asymptomatic.
